Survodutide in MASH: bridging the gap between hepatic and systemic metabolic dysfunction

📖 Top 20% JournalDec 12, 2024Expert opinion on investigational drugs

Survodutide’s effects on liver and whole-body metabolism in MASH

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

Survodutide, an investigational dual agonist, targets both the glucagon receptor and GLP-1 receptor.

Survodutide shows promise in managing obesity and metabolic dysfunction-associated steatohepatitis (MASH).
The dual activation of glucagon and GLP-1 receptors may enhance metabolic benefits compared to selective GLP-1 receptor agonists.
Clinical trials indicate that survodutide is generally well tolerated, with primarily manageable gastrointestinal side effects.
Efficacy in promoting fibrosis regression in MASH remains to be proven as survodutide advances through phase 3 clinical development.

AI simplified

INTRODUCTION: Glucagon-like peptide-1 receptor (GLP-1 R) agonists have demonstrated remarkable effectiveness in the treatment of obesity and type 2 diabetes. Although these agents provide beneficial effects for metabolic dysfunction-associated steatohepatitis (MASH) through their glucose-lowering and weight-reducing properties, their efficacy in promoting fibrosis regression remains unproven. Survodutide, an investigational dual agonist that simultaneously targets both the glucagon receptor (GCGR) and GLP-1 R, has emerged as a promising therapeutic candidate for the comprehensive management of obesity and MASH. By engaging these two critical receptors, this drug has the potential to offer a broad spectrum of metabolic benefits, addressing multiple pathogenic mechanisms underlying these interrelated disorders.

AREAS COVERED: This review examines the pharmacological profile, clinical efficacy, and safety data of survodutide derived from phase 1 and 2 clinical trials.

EXPERT OPINION: Survodutide's dual agonism of the GCGR and GLP-1 R may surpass the efficacy of selective GLP-1 R agonists, demonstrating significant potential in resolving MASH and promoting fibrosis regression. The drug is generally well tolerated, with primarily manageable gastrointestinal adverse effects. As survodutide progresses through phase 3 clinical development, its potential to provide a more effective and holistic approach to treating MASH and its comorbidities may significantly improve patient outcomes and quality of life.

Full Text

Full text is available at the source.

View full text ↗

Abstract

Full Text

Related papers